These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 25733827)

  • 1. Antibiotics against Pseudomonas aeruginosa for COPD exacerbation in ICU: a 10-year retrospective study.
    Planquette B; Péron J; Dubuisson E; Roujansky A; Laurent V; Le Monnier A; Legriel S; Ferre A; Bruneel F; Chiles PG; Bedos JP
    Int J Chron Obstruct Pulmon Dis; 2015; 10():379-88. PubMed ID: 25733827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa.
    Lin SH; Kuo PH; Hsueh PR; Yang PC; Kuo SH
    Respirology; 2007 Jan; 12(1):81-7. PubMed ID: 17207030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic-resistant
    Gao YH; Guan WJ; Zhu YN; Chen RC; Zhang GJ
    Int J Chron Obstruct Pulmon Dis; 2018; 13():237-246. PubMed ID: 29386892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: Prevalence, risk factors, and outcome.
    Nseir S; Di Pompeo C; Cavestri B; Jozefowicz E; Nyunga M; Soubrier S; Roussel-Delvallez M; Saulnier F; Mathieu D; Durocher A
    Crit Care Med; 2006 Dec; 34(12):2959-66. PubMed ID: 17012911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nebulized Colistin And Continuous Cyclic Azithromycin In Severe COPD Patients With Chronic Bronchial Infection Due To
    Montón C; Prina E; Pomares X; Cugat JR; Casabella A; Oliva JC; Gallego M; Monsó E
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2365-2373. PubMed ID: 31802860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study.
    Bouglé A; Foucrier A; Dupont H; Montravers P; Ouattara A; Kalfon P; Squara P; Simon T; Amour J;
    Trials; 2017 Jan; 18(1):37. PubMed ID: 28114979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease.
    Almagro P; Salvadó M; Garcia-Vidal C; Rodríguez-Carballeira M; Cuchi E; Torres J; Heredia JL
    Respiration; 2012; 84(1):36-43. PubMed ID: 21996555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia.
    Rello J; Rodriguez A; Torres A; Roig J; Sole-Violan J; Garnacho-Montero J; de la Torre MV; Sirvent JM; Bodi M
    Eur Respir J; 2006 Jun; 27(6):1210-6. PubMed ID: 16510452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN; Micek ST; Reichley RM; Ritchie DJ
    Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease.
    Rosell A; Monsó E; Soler N; Torres F; Angrill J; Riise G; Zalacaín R; Morera J; Torres A
    Arch Intern Med; 2005 Apr; 165(8):891-7. PubMed ID: 15851640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD.
    Wilson R; Anzueto A; Miravitlles M; Arvis P; Haverstock D; Trajanovic M; Sethi S
    Int J Chron Obstruct Pulmon Dis; 2015; 10():985-93. PubMed ID: 26082623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of empirical antipseudomonal antibiotic prescription for adults with pneumonia in the emergency department.
    Angrill N; Gallego M; Font J; Vallés J; Morón A; Monsó E; Rello J
    BMC Pulm Med; 2020 Apr; 20(1):83. PubMed ID: 32245452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa.
    Sullivan E; Bensman J; Lou M; Agnello M; Shriner K; Wong-Beringer A
    Crit Care Med; 2014 Jan; 42(1):48-56. PubMed ID: 23963124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance.
    Micek ST; Wunderink RG; Kollef MH; Chen C; Rello J; Chastre J; Antonelli M; Welte T; Clair B; Ostermann H; Calbo E; Torres A; Menichetti F; Schramm GE; Menon V
    Crit Care; 2015 May; 19(1):219. PubMed ID: 25944081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health care-associated pneumonia (HCAP): empiric antibiotics targeting methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa predict optimal outcome.
    Micek ST; Reichley RM; Kollef MH
    Medicine (Baltimore); 2011 Nov; 90(6):390-395. PubMed ID: 22033455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life data on antibiotic prescription and sputum culture diagnostics in acute exacerbations of COPD in primary care.
    Bathoorn E; Groenhof F; Hendrix R; van der Molen T; Sinha B; Kerstjens HA; Friedrich AW; Kocks JW
    Int J Chron Obstruct Pulmon Dis; 2017; 12():285-290. PubMed ID: 28144133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of respiratory viral assay panel on antibiotic prescription patterns at discharge in adults admitted with mild to moderate acute exacerbation of COPD: a retrospective before- after study.
    Tickoo M; Ruthazer R; Bardia A; Doron S; Andujar-Vazquez GM; Gardiner BJ; Snydman DR; Kurz SG
    BMC Pulm Med; 2019 Jul; 19(1):118. PubMed ID: 31262278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic antibiotics for Pseudomonas aeruginosa infection in outpatients with non-hospitalised exacerbations of pre-existing lung diseases: a randomised clinical trial.
    Eklöf J; Alispahic IA; Armbruster K; Lapperre TS; Browatzki A; Overgaard RH; Harboe ZB; Janner J; Moberg M; Ulrik CS; Andreassen HF; Weinreich UM; Kjærgaard JL; Villadsen J; Fenlev CS; Jensen TT; Christensen CW; Bangsborg J; Ostergaard C; Ghathian KSA; Jordan A; Klausen TW; Nielsen TL; Wilcke T; Seersholm N; Sivapalan P; Jensen JS
    Respir Res; 2024 Jun; 25(1):236. PubMed ID: 38844921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of a nosocomial outbreak by alginate-producing pan-antibiotic-resistant Pseudomonas aeruginosa.
    Yakupogullari Y; Otlu B; Dogukan M; Gursoy C; Korkmaz E; Kizirgil A; Ozden M; Durmaz R
    Am J Infect Control; 2008 Dec; 36(10):e13-8. PubMed ID: 19084158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudomonas aeruginosa resistance patterns and clinical outcomes in hospitalized exacerbations of COPD.
    Rodrigo-Troyano A; Suarez-Cuartin G; Peiró M; Barril S; Castillo D; Sanchez-Reus F; Plaza V; Restrepo MI; Chalmers JD; Sibila O
    Respirology; 2016 Oct; 21(7):1235-42. PubMed ID: 27325555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.